Breaking News: Embargoed Feed - hidden

Filters close
Go to Advanced Search
Released: 13-May-2025 5:00 AM EDT
Diffinvex Reveals How Cancers Rewire Driver Genes to Beat Chemotherapy
 Fundació Institut de Recerca Biomèdica (IRB BARCELONA)

● IRB Barcelona researchers have developed a new computational tool that tracks the evolutionary shifts in selection pressure during tumorigenesis and chemotherapy. ● Using more than 8,500 cancer whole-genome sequences, the team identified 11 cancer driver genes linked to chemoresistance to specific anticancer drugs. ● The study has been published in the journal Nature Communications.

Comment
access_time Embargo lifts in 2 days
This news release is embargoed until 15-May-2025 5:00 AM EDT Released to reporters: 13-May-2025 4:40 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 15-May-2025 5:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 15-May-2025 5:00 PM EDT Released to reporters: 12-May-2025 6:40 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 15-May-2025 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 13-May-2025 7:00 AM EDT Released to reporters: 12-May-2025 6:30 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 13-May-2025 7:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 19-May-2025 9:05 AM EDT Released to reporters: 12-May-2025 6:20 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 19-May-2025 9:05 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 19-May-2025 9:20 AM EDT Released to reporters: 12-May-2025 5:25 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 19-May-2025 9:20 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 19-May-2025 9:00 AM EDT Released to reporters: 12-May-2025 5:25 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 19-May-2025 9:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Not for public release

This news release is embargoed until 12-May-2025 5:00 PM EDT Released to reporters: 6-May-2025 8:10 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 12-May-2025 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Not for public release

This news release is embargoed until 12-May-2025 5:00 PM EDT Released to reporters: 6-May-2025 8:25 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 12-May-2025 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Not for public release

This news release is embargoed until 12-May-2025 5:00 PM EDT Released to reporters: 6-May-2025 8:05 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 12-May-2025 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 19-May-2025 12:00 AM EDT Released to reporters: 12-May-2025 11:10 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 19-May-2025 12:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
Released: 12-May-2025 11:00 AM EDT
Drug to Slow Alzheimer’s Well Tolerated Outside of Clinical Trial Setting
 Washington University in St. Louis

In a recent study, researchers at WashU Medicine found adverse events were rare and manageable among clinic patients with very mild or mild Alzheimer’s disease who received lecanemab infusions at the Memory Diagnostic Center at WashU Medicine.

Comment

Not for public release

This news release is embargoed until 15-May-2025 2:00 PM EDT Released to reporters: 12-May-2025 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 15-May-2025 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 21-May-2025 2:00 PM EDT Released to reporters: 12-May-2025 9:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 21-May-2025 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 14-May-2025 2:00 PM EDT Released to reporters: 12-May-2025 7:50 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 14-May-2025 2:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
Released: 11-May-2025 12:00 AM EDT
Mother of Twins Travels From Germany to Chicago for Life-Saving Lung Transplant After Being Diagnosed with Terminal Lung Cancer
 Northwestern Medicine

Mother of twins travels from Germany to Chicago for life-saving lung transplant after being diagnosed with terminal lung cancer

Comment
Released: 10-May-2025 2:00 PM EDT
Environmental Chemical Impacts Neurodevelopment
 Society of Toxicology

Comment

Not for public release

This news release is embargoed until 14-May-2025 5:00 PM EDT Released to reporters: 9-May-2025 5:10 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 14-May-2025 5:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 14-May-2025 8:00 AM EDT Released to reporters: 9-May-2025 10:50 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 14-May-2025 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
access_time Embargo lifts in 2 days
This news release is embargoed until 19-May-2025 12:00 PM EDT Released to reporters: 9-May-2025 9:10 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 19-May-2025 12:00 PM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.


close
1.77145